CliffBio
small molecule

DAPZURA RT

DAPTOMYCIN

Loss of exclusivityMarch 2041latest FDA-listed patent expiry
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPZURA RT
Active ingredientDAPTOMYCIN
Strength500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 2022
Marketing statusDISCN

Listed patents

PatentExpiresType
11173189March 2041product

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DAPZURA RT patent cliff — loss of exclusivity March 2041 | CliffBio